Programme (Click here)
Rachel Tyndale PhD is head of Pharmacogenetics at the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, the Canada Research Chair in Pharmacogenomics. She is a Professor in the Departments of Pharmacology & Toxicology, and Psychiatry at the University of Toronto. Dr. Tyndale focuses on sources of variation between individuals in drug response in the clinical area of addictions and mental health. Dr. Tyndale seeks to identify and understand risk factors, and underlying mechanisms, in substance dependence and to implement approaches to personalize treatment. Her laboratory program also has a major interest in understanding how interindividual variation in drug metabolizing enzymes within the brain alter drug and toxin effects.
Dr. Tyndale sits on numerous scientific advisory boards, editorial boards, chaired NIH’s PharmacoGenomics Research Network (PGRN.org), and was a lead on the Surgeon General’s Report on Tobacco Cessation. Dr. Tyndale has supervised over 100 scientists, post-doctoral fellows and graduate students, published over 400 papers and book chapters, given over 250 invited presentations and received over 50 awards in clinical and basic pharmacology, neuroscience and genetics.
Dr. Rigotti is a Professor of Medicine at Harvard Medical School and founding director of Massachusetts General Hospital’s Tobacco Research and Treatment Center. A board-certified general internist, Dr. Rigotti is internationally known for her research to reduce the health burden of tobacco use by evaluating tobacco cessation treatments and promoting their adoption in health care settings, both inpatient and outpatient. Dr. Rigotti was a member of the National Academies of Science, Engineering, and Medicine panel that produced the landmark 2018 report, Public Health Consequences of E-Cigarettes. Her current work includes addressing the role of e-cigarettes for tobacco smoking cessation and harm reduction.
Dr. Rigotti has authored over 300 publications and served as President of the Society for Research in Nicotine and Tobacco and as President of the Society of General Internal Medicine, which in 2015 awarded her its highest research award the John Eisenberg National Award for Career Achievement in Research. She is an elected member of the American Association of Physicians and a graduate of Stanford University and Harvard Medical School.
Ann McNeill is a Professor of Tobacco Addiction at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London, where she established and leads the Nicotine Research Group. Ann has worked in tobacco research since the mid 1980s and has been at the heart of developing the evidence base for nicotine and tobacco control policy in the UK and internationally. For her accomplishments, she was awarded the WHO World No Tobacco Day Tobacco Control Medal in 1998, and a fellow of the international Society for Research on Nicotine and Tobacco (SRNT) in 2019, and the SRNT Doll-Wynder award in 2019/2020. Ann was also made an National Institute of Health Research (NIHR) Senior Investigator in 2019.
Professor McNeill has published over 300 peer-reviewed papers and numerous national and governmental reports. Since 2015, she has been named among the global top 1% of most cited researchers in her field by Thomson Reuters/Clarivate Analytics. Ann’s research spans prevention, cessation and harm reduction. Recently, she has led five evidence reviews on e-cigarettes commissioned by Public Health England and since 1992, she has contributed to several reports by the Royal College of Physicians in England on aspects of smoking and tobacco. In addition, she has demonstrated a sustained interest in smoking and inequalities, particularly reducing smoking among those with mental health problems. Ann also co-chairs the national Mental Health & Smoking Partnership.
Ann is also Vice Dean (Culture, Diversity & Inclusion) at the IoPPN where she leads faculty-wide initiatives to foster an inclusive and supportive culture. She chairs the faculty Self-Assessment Team which currently has an active membership of around 50 academic, research and professional service staff as well as student representatives. She has also established working groups and champions to lead initiatives on specific protected characteristics. Ann mentors extensively, including researchers in and from low and middle income countries.
Prof. Joachim Marti is an Associate Professor in health economics at the University Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland. After completing his PhD in public economics focused on smoking behaviour and tobacco regulation at the University of Neuchâtel, Switzerland, he pursued a postdoctoral fellowship at the Yale School of Public Health and then held teaching and research positions at the University of Leeds and at the Centre for Health Policy at Imperial College London.
Joachim has worked on the empirical evaluation of tobacco control interventions, including smoking bans, tobacco control expenditures, and taxation. Some of his work also focused on the interaction between insurance coverage, smoking decisions, and use of smoking cessation drugs. In another strand of work, he applied stated preferences methods, including discrete choice experiments, to investigate preferences for various nicotine-delivery products, including e-cigarettes and NRTs.
More generally, his research looks at the efficiency and equity impact of health care interventions and policies using large administrative datasets, explores the use of behavioural economics to inform health policy, and investigates new health care delivery and financing models.
Unisanté propose, le 16 septembre 2021, une conférence satellite francophone. Les thématiques suivantes concernant le tabac et la nicotine seront abordées :
Pour afficher uniquement le programme de la conférence satellite, cliquez sur le bouton 'Thu Sep 16' et sélectionnez dans le menu à droite 'Tracks' : Session francophone